PTK2B and cancer: Here, it was intriguing that TPK ECOs displayed lower sensitivity to drugs targeting the PTK pathway, compared to the other three ECOs (Figure 6C), consistent with the resistance of Kras mutant cancers to targeted therapies as previously reported.[28] The mechanism of Kras mutation‐induced drug resistance in EC requires further study.